RT Journal Article
SR Electronic
T1 Safety and Effectiveness of SA58 Nasal Spray against COVID-19 Infection in Medical Personnel:An Open-label, Blank-controlled Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.27.22283698
DO 10.1101/2022.12.27.22283698
A1 Shujie Si
A1 Canrui Jin
A1 Yunlong Cao
A1 Jianping Li
A1 Biao Kan
A1 Feng Xue
A1 Xiaoliang Sunney Xie
A1 Liang Fang
A1 Gang Zeng
A1 Shuo Zhang
A1 Yaling Hu
A1 Xiaoping Dong
YR 2022
UL http://medrxiv.org/content/early/2022/12/31/2022.12.27.22283698.abstract
AB Approved COVID-19 vaccines to date have limited effectiveness in protecting infection and blocking transmission. A nasal spray of broad-spectrum antibody against COVID-19 (SA58 Nasal Spray) has recently been developed by Sinovac Life Sciences Co., Ltd.. From October 31 to November 30, 2022, an open-label, blank controlled study on the SA58 Nasal Spray against COVID-19 infection was conducted with the medical personnel working in the designated COVID-19 hospitals and Fangcang shelter hospitals (alternate care sites) of COVID-19 cases in Hohhot city, the Inner Mongolia Autonomous Region. A total of 6662 medical personnel were involved in this study: 3368 used SA58 Nasal Spray from the drug group, and 3294 not used from blank control group. The medication was self-administered intranasally 1∼2 times per day with an interval of 6 hours for 30 days.. The safety results indicated that the SA58 Nasal Spray was well tolerant. The incidence of adverse events (AEs) was 28.6% (497/1736), and the majority of the AEs were mild and from administrative site. 135 COVID-19 cases were identified for SARS-CoV-2 by RT-PCR during the 30-day observation. The cumulative incidence of COVID-19 in the drug group and the control group were 0.026% and 0.116%, respectively. The effectiveness of the SA58 Nasal Spray for preventing COVID-19 infection among medical personnel was evaluated as 77.7% (95% CI: 52.2% - 89.6%). In conclusion, the SA58 Nasal Spray is well-tolerant and highly effective against COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05664919Funding StatementThis study work was supported by Sinovac Life Sciences Co., Ltd.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study received approval from the Institutional Review Board of the Inner Mongolia Fourth Hospital (202223).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.